Haleon (LON:HLN) Shares Down 1.1% – Should You Sell?

Shares of Haleon plc (LON:HLN) fell 1.1% on Tuesday . The company traded as low as GBX 374.50 ($4.86) and last traded at GBX 374.50 ($4.86). 10,110,692 shares were traded during trading, a decline of 49% from the average session volume of 19,871,000 shares. The stock had previously closed at GBX 378.50 ($4.91).

Analyst Upgrades and Downgrades

Separately, Berenberg Bank boosted their price target on Haleon from GBX 410 ($5.32) to GBX 447 ($5.80) and gave the company a “buy” rating in a research note on Monday, August 5th.

Haleon Stock Performance

The stock has a market capitalization of £33.85 billion, a P/E ratio of 3,120.83, a PEG ratio of 1.49 and a beta of 0.19. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 54.18. The firm has a 50-day moving average of GBX 384.37 and a 200 day moving average of GBX 352.55.

Haleon Cuts Dividend

The firm also recently announced a dividend, which was paid on Thursday, September 19th. Stockholders of record on Thursday, August 15th were given a dividend of GBX 2 ($0.03) per share. The ex-dividend date was Thursday, August 15th. This represents a dividend yield of 0.57%. Haleon’s dividend payout ratio (DPR) is currently 5,000.00%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.